Musical hairs: Alopecia bid Concert's next play, phase I to JAK up in second quarter
By Randy Osborne
Staff Writer
Staff Writer
With the FDA having specifically called out alopecia areata in its list of patient-focused drug development concerns, Concert Pharmaceuticals Inc. could be "in the right place at the right time" with new pipeline candidate CTP-543.
